BICYCLE THERAPEUTICS PLC-ADR Business Summary

Bicycle Therapeutics PLC (BCYC) is a clinical-stage biopharmaceutical company pioneering a proprietary class of synthetic, constrained short peptides known as "Bicycles." The company generates revenue primarily through strategic licensing agreements, milestone payments, and R&D collaborations with global pharmaceutical entities, as well as interest income from its substantial cash reserves. Its business is organized into two primary geographic segments, the United Kingdom and the United States, with the majority of revenue derived from U.S. operations. The firm’s pipeline focuses on three distinct modalities: Bicycle Toxin Conjugates (BTCs), Bicycle Tumor-Targeted Immune Cell Agonists (TICAs), and Bicycle Radioconjugates (BRCs). In the competitive landscape, Bicycle Therapeutics competes with oncology-focused biotech firms such as Zymeworks, Sutro Biopharma, and ADC-specialists like Seagen (Pfizer). BCYC distinguishes itself by offering the high affinity and specificity of antibodies combined with the rapid tissue penetration and tunable pharmacokinetics of small molecules, positioning it as a leader in the emerging field of constrained peptide therapeutics. Leadership is spearheaded by CEO Kevin Lee, Ph.D., who joined from Pfizer in 2015 and has overseen the company’s transition to a pivotal clinical-stage entity. As of February 2026, the executive team includes Travis Thompson as Chief Financial Officer (formerly of EY), Michael Method, M.D., as Chief Medical Officer (formerly of ImmunoGen and Eli Lilly), and Michael Skynner, Ph.D., who recently transitioned from CTO to Chief Scientific Officer. The company was co-founded by Nobel Laureate Sir Gregory Winter, a pioneer in monoclonal antibodies, and Professor Christian Heinis of EPFL. Bicycle Therapeutics is backed by a high-pedigree board and institutional investor base, most notably Baker Bros. Advisors LP, which maintains a dominant ownership stake of approximately 44%, alongside other major investors such as Perceptive Advisors and Vertex Growth.